Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection
Top Cited Papers
- 3 September 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (18) , 5843-5855
- https://doi.org/10.1021/jm800245z
Abstract
Human immunodeficiency virus type-1 (HIV-1) integrase is one of the three virally encoded enzymes required for replication and therefore a rational target for chemotherapeutic intervention in the treatment of HIV-1 infection. We report here the discovery of Raltegravir, the first HIV-integrase inhibitor approved by FDA for the treatment of HIV infection. It derives from the evolution of 5,6-dihydroxypyrimidine-4-carboxamides and N-methyl-4-hydroxypyrimidinone-carboxamides, which exhibited potent inhibition of the HIV-integrase catalyzed strand transfer process. Structural modifications on these molecules were made in order to maximize potency as HIV-integrase inhibitors against the wild type virus, a selection of mutants, and optimize the selectivity, pharmacokinetic, and metabolic profiles in preclinical species. The good profile of Raltegravir has enabled its progression toward the end of phase III clinical trials for the treatment of HIV-1 infection and culminated with the FDA approval as the first HIV-integrase inhibitor for the treatment of HIV-1 infection.Keywords
This publication has 20 references indexed in Scilit:
- Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialThe Lancet, 2007
- Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 ActivityAntimicrobial Agents and Chemotherapy, 2005
- Integrase inhibitors to treat HIV/AidsNature Reviews Drug Discovery, 2005
- Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus MacaquesScience, 2004
- Discovery of α,γ-Diketo Acids as Potent Selective and Reversible Inhibitors of Hepatitis C Virus NS5b RNA-Dependent RNA PolymeraseJournal of Medicinal Chemistry, 2003
- Enfuvirtide (T-20): A Novel Human Immunodeficiency Virus Type 1 Fusion InhibitorClinical Infectious Diseases, 2003
- Design and Synthesis of 8-Hydroxy-[1,6]Naphthyridines as Novel Inhibitors of HIV-1 Integrase in Vitro and in Infected CellsJournal of Medicinal Chemistry, 2003
- Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymesProceedings of the National Academy of Sciences, 2002
- Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in CellsScience, 2000
- HIV Integrase Structure and FunctionPublished by Elsevier ,1999